223 related articles for article (PubMed ID: 21356389)
1. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.
Shibata T; Kokubu A; Miyamoto M; Sasajima Y; Yamazaki N
Am J Pathol; 2011 Mar; 178(3):1395-402. PubMed ID: 21356389
[TBL] [Abstract][Full Text] [Related]
2. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.
Hou P; Liu D; Dong J; Xing M
Cell Cycle; 2012 Jan; 11(2):286-95. PubMed ID: 22189819
[TBL] [Abstract][Full Text] [Related]
3. Novel somatic mutations to PI3K pathway genes in metastatic melanoma.
Shull AY; Latham-Schwark A; Ramasamy P; Leskoske K; Oroian D; Birtwistle MR; Buckhaults PJ
PLoS One; 2012; 7(8):e43369. PubMed ID: 22912864
[TBL] [Abstract][Full Text] [Related]
4. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
5. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
[TBL] [Abstract][Full Text] [Related]
6. RAF265 inhibits the growth of advanced human melanoma tumors.
Su Y; Vilgelm AE; Kelley MC; Hawkins OE; Liu Y; Boyd KL; Kantrow S; Splittgerber RC; Short SP; Sobolik T; Zaja-Milatovic S; Dahlman KB; Amiri KI; Jiang A; Lu P; Shyr Y; Stuart DD; Levy S; Sosman JA; Richmond A
Clin Cancer Res; 2012 Apr; 18(8):2184-98. PubMed ID: 22351689
[TBL] [Abstract][Full Text] [Related]
7. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM
Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719
[TBL] [Abstract][Full Text] [Related]
8. P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b.
Naffa R; Vogel L; Hegedűs L; Pászty K; Tóth S; Kelemen K; Singh N; Reményi A; Kállay E; Cserepes M; Tóvári J; Grusch M; Enyedi Á
Cells; 2020 May; 9(5):. PubMed ID: 32414111
[TBL] [Abstract][Full Text] [Related]
9. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
10. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
van den Hurk K; Balint B; Toomey S; O'Leary PC; Unwin L; Sheahan K; McDermott EW; Murphy I; van den Oord JJ; Rafferty M; FitzGerald DM; Moran J; Cummins R; MacEneaney O; Kay EW; O'Brien CP; Finn SP; Heffron CC; Murphy M; Yela R; Power DG; Regan PJ; McDermott CM; O'Keeffe A; Orosz Z; Donnellan PP; Crown JP; Hennessy BT; Gallagher WM
Melanoma Res; 2015 Jun; 25(3):189-99. PubMed ID: 25746038
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
[TBL] [Abstract][Full Text] [Related]
12. The plasma membrane Ca
Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
[TBL] [Abstract][Full Text] [Related]
13. Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.
Loria R; Bon G; Perotti V; Gallo E; Bersani I; Baldassari P; Porru M; Leonetti C; Di Carlo S; Visca P; Brizzi MF; Anichini A; Mortarini R; Falcioni R
Oncotarget; 2015 Feb; 6(5):2779-93. PubMed ID: 25576923
[TBL] [Abstract][Full Text] [Related]
14. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
[TBL] [Abstract][Full Text] [Related]
15. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
16. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda L; Del Bufalo D; Desideri M; Di Sanza C; Stoppacciaro A; Ricciardi MR; Chiaretti S; Tavolaro S; Benassi B; Bellacosa A; Foà R; Tafuri A; Cognetti F; Anichini A; Zupi G; Milella M
Neoplasia; 2009 Aug; 11(8):720-31. PubMed ID: 19649202
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Calvert AE; Chalastanis A; Wu Y; Hurley LA; Kouri FM; Bi Y; Kachman M; May JL; Bartom E; Hua Y; Mishra RK; Schiltz GE; Dubrovskyi O; Mazar AP; Peter ME; Zheng H; James CD; Burant CF; Chandel NS; Davuluri RV; Horbinski C; Stegh AH
Cell Rep; 2017 May; 19(9):1858-1873. PubMed ID: 28564604
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
19. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
Yancovitz M; Litterman A; Yoon J; Ng E; Shapiro RL; Berman RS; Pavlick AC; Darvishian F; Christos P; Mazumdar M; Osman I; Polsky D
PLoS One; 2012; 7(1):e29336. PubMed ID: 22235286
[TBL] [Abstract][Full Text] [Related]
20. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Murugan AK; Bojdani E; Xing M
Biochem Biophys Res Commun; 2010 Mar; 393(3):555-9. PubMed ID: 20171178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
